Browse All

Current Filters

CLEAR FILTER x

TITLE

Long-term Efficacy and Safety of Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Final Analysis of the Phase 3 CHAMPION-NMOSD Trial

Author:Pittock, Sean   Barnett, Michael   Bennett, Jeffrey   Berthele, Achim   de Sèze, Jérôme   Levy, Michael   Nakashima, Ichiro   Oreja-Guevara, Celia   Palace, Jacqueline   Paul, Friedemann   Pozzilli, Carlo   Allen, Kerstin   Parks, Becky   Kim, Ho Jin   

Session Name:P7: Autoimmune Neurology: NMOSD/MOGAD 6  

Topic:Autoimmune Neurology  

Program Number:P7.012  

Author Institution:Mayo Clinic, Rochester, MN  University of Sydney, Sydney, New South Wales, Australia  University of Colorado, Anschutz Medical Campus, Aurora, CO  School of Medicine and Health, Technical University of Munich, Munich, Germany  University Hospital of Strasbourg, Strasbourg, France  Massachusetts General Hospital and Harvard Medical School, Boston, MA  Tohoku Medical and Pharmaceutical University , Sendai, Japan  San Carlos Clinical Hospital and Complutense University of Madrid, Madrid, Spain  John Radcliff Hospital, Oxford, United Kingdom  Charité-Universitätsmedizin Berlin and Max Delbrück Centre for Molecular Medicine, Berlin, Germany  Sapienza University, Rome, Italy  Alexion, AstraZeneca Rare Disease, Boston, MA  National Cancer Center, Goyang, Korea, Republic of  

Pregnancy Outcomes and Disease Activity in Women With NMOSD and MOGAD

Author:Blum, Nina   Dost-Kovalsky, Karen   Roettger, Sina   Wenzel, Saskia   Haben, Sabrina   Bast, Nadine   Bayer, Kaya   Berthele, Achim   Kuempfel, Tania   Ringelstein, Marius   Aktas, Orhan   Wildemann, Brigitte   Rothhammer, Veit   Yalachkov, Yavor   Weber, Martin   Klotz, Luisa   Hümmert, Martin   Paul, Friedemann   Naumann, Jasmin   Herwerth, Marina   Häußler, Vivien   Ayzenberg, Ilya   Thiel, Sandra   Hellwig, Kerstin   

Session Name:P8: Multiple Sclerosis: NMOSD, MOGAD, and Other Mimickers of MS 3  

Topic:Multiple Sclerosis  

Program Number:P8.006  

Author Institution:Department of Neurology, St. Josef Hospital, Ruhr University, Bochum, Germany, Bochum, Germany  School of Medicine, Technical University Munich, Klinikum rechts der Isar, Muenchen, Germany  Institute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany  Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany, Germany  University Hospital Heidelberg, Department of Neurology, Heidelberg, Germany  Department of Neurology, University Hospital Erlangen-Nuernberg, Erlangen, Germany  Department of Neurology, University Medicine Frankfurt, Goethe University Frankfurt, Frankfurt, Germany, Frankfurt, Germany  Department of Neurology, University Medical Center Göttingen , Göttingen, Germany  Department of Neurology, University Hospital Münster, Münster, Germany  Department of Neurology, Medizinische Hochschule Hannover, Hannover, Germany  Department of Neurology, Charite ,Berlin, Berlin, Germany  Department of Neurology, Knappschaft Kliniken Sulzbach, Sulzbach, Germany, Sulzbach, Germany  Department of Neurology, University Hospital Zurich, Zurich, Switzerland  Department of Neurology, University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany  

Design of Phase Three of KYSA-6, a Global Open-label, Randomized, Controlled Study of KYV-101, a Fully Human CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy, Versus Ongoing Standard-of-Care (SOC) Immunosuppressive Therapy in Generalized Myasthenia Gr

Author:Mupiddi, Sri   Hunter, Michael C   Hoffmann, Sarah   Hegelmaier, Tobias   Motte, Jeremias   Gold, Ralf   Mougiakakos, Dimitrios   Schubert, Charlotte   Schreiber, Stefanie   Habib, Ali   Geis, Christian   Carbunar, Olimpia   Shroff, Sheetal   Dalakas, Marinos   Berthele, Achim   Shieh, Perry   Barboi, Alexandru   Dutra, Livia   Alsolaihim, Alanood   Needham, Edward   Norwood, Fiona   Cutter, Gary R   Hunter, Brad   Chou, Justin   Xing, Baodong   Borie, Dominic   Gehchan, Naji   Haghikia, Aiden   

Session Name:P9: Neuromuscular and Clinical Neurophysiology (EMG): Myasthenia Gravis Clinical Trials  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:P9.011  

Author Institution:Stanford, CA  Intermountain Medical Center, UT  Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany  Hannover Medical School, Germany  Ruhr University Bochum, Germany  Otto von Guericke University Magdeburg, Magdeburg, Germany  University Medical Center Hamburg-Eppendorf, Germany  Otto-von-Guericke University Magdeburg, Germany  University of California, Irvine, Orange, CA  Jena University Hospital, Germany  University of Miami, Miami, FL  Houston Methodist Hospital, Houston, TX  Thomas Jefferson University, Philadelphia, PA  School of Medicine, Technical University Munich, Klinikum rechts der Isar, Dept., Muenchen, Germany  University of California Los Angeles, Los Angeles, CA  Indiana University Health, IN  Instituto do Cérebro do Hospital Israelita Albert Einstein, Brazil  King Faisal Specialist Hospital and Research Center, Saudi Arabia  University of Cambridge, United Kingdom  Kings College Hospital, United Kingdom  University of Alabama , AL  Intermountain Health, UT  Kyverna Therapeutics Inc., CA  Kyverna Therapeutics Inc., Emeryville, CA  Hannover Medical School, Hannover, Germany